TY - JOUR AU - Antoni, S. AU - Ferlay, J. AU - Soerjomataram, I. PY - 2017 DA - 2017// TI - Bladder Cancer incidence and mortality: a global overview and recent trends JO - Eur Urol VL - 71 UR - https://doi.org/10.1016/j.eururo.2016.06.010 DO - 10.1016/j.eururo.2016.06.010 ID - Antoni2017 ER - TY - JOUR AU - Tanaka, T. AU - Miyazawa, K. AU - Tsukamoto, T. AU - Kuno, T. AU - Suzuki, K. PY - 2011 DA - 2011// TI - Pathobiology and chemoprevention of bladder Cancer JO - J Oncol VL - 2011 ID - Tanaka2011 ER - TY - JOUR AU - Cabello, M. J. AU - Grau, L. AU - Franco, N. AU - Orenes, E. AU - Alvarez, M. AU - Blanca, A. AU - Heredero, O. AU - Palacios, A. AU - Urrutia, M. AU - Fernández, J. M. AU - López-Beltrán, A. AU - Sánchez-Carbayo, M. PY - 2011 DA - 2011// TI - Multiplexed methylation profiles of tumor suppressor genes in bladder Cancer JO - J MolDiagn VL - 13 ID - Cabello2011 ER - TY - JOUR AU - Pasbos, C. L. PY - 2002 DA - 2002// TI - Bladder cancer, epidemiology, diagnosis, and management JO - Cancer Pract VL - 10 UR - https://doi.org/10.1046/j.1523-5394.2002.106011.x DO - 10.1046/j.1523-5394.2002.106011.x ID - Pasbos2002 ER - TY - BOOK AU - Ferlay, J. AU - Bray, F. AU - Pisani, P. AU - Parkin, D. M. PY - 2001 DA - 2001// TI - GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase no. 5 PB - IARC Press CY - Lyon ID - Ferlay2001 ER - TY - JOUR AU - Uekado, Y. AU - Hirano, A. AU - Shinka, T. AU - Ohkawa, T. PY - 1994 DA - 1994// TI - The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guerin for prophylaxis of recurrence of superficial bladder cancer: a preliminary report JO - Cancer Chemother Pharmacol VL - 35 UR - https://doi.org/10.1007/BF00686923 DO - 10.1007/BF00686923 ID - Uekado1994 ER - TY - JOUR AU - Ray, E. R. AU - O’Brien, T. S. PY - 2006 DA - 2006// TI - Approaches to reducing recurrence in superficial bladder cancer JO - Eur Kidney Urol Dis VL - 1 ID - Ray2006 ER - TY - JOUR AU - Herr, H. W. AU - Laudone, V. P. AU - Whitmore, W. F. PY - 1987 DA - 1987// TI - An overview of intravesical therapy for superficial bladder tumors JO - J Urol VL - 138 UR - https://doi.org/10.1016/S0022-5347(17)43644-5 DO - 10.1016/S0022-5347(17)43644-5 ID - Herr1987 ER - TY - JOUR AU - Whelan, P. PY - 2007 DA - 2007// TI - The treatment of non-muscle-invasive bladder Cancer with Intravesical chemotherapy and immunotherapy JO - Eur Urol Suppl VL - 6 UR - https://doi.org/10.1016/j.eursup.2007.01.028 DO - 10.1016/j.eursup.2007.01.028 ID - Whelan2007 ER - TY - JOUR AU - Stadler, W. M. AU - Kuzel, T. AU - Roth, B. PY - 1997 DA - 1997// TI - Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer JO - J Clin Oncol VL - 15 UR - https://doi.org/10.1200/JCO.1997.15.11.3394 DO - 10.1200/JCO.1997.15.11.3394 ID - Stadler1997 ER - TY - JOUR AU - Plunkett, W. AU - Huang, P. AU - Searcy, C. E. PY - 1996 DA - 1996// TI - Gemcitabine: preclinical pharmacology and mechanisms of action JO - Semin Oncol VL - 23 ID - Plunkett1996 ER - TY - JOUR AU - Joudi, F. N. AU - O’Donnel, M. A. PY - 2004 DA - 2004// TI - Second-line intravesical therapy versus cystectomy for Bacile Calmette-Gue’rin (BCG) failure JO - Curr Opin Urol VL - 14 UR - https://doi.org/10.1097/00042307-200409000-00005 DO - 10.1097/00042307-200409000-00005 ID - Joudi2004 ER - TY - JOUR AU - Liberati, A. AU - Altman, D. G. AU - Tetzlaff, J. PY - 2009 DA - 2009// TI - The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration JO - J Clin Epidemiol VL - 62 UR - https://doi.org/10.1016/j.jclinepi.2009.06.006 DO - 10.1016/j.jclinepi.2009.06.006 ID - Liberati2009 ER - TY - STD TI - Dong ZL, Yang KH, Liu YL, Mi DH, Wang ZP, Tian JH. Intravesical doxorubicin versus epirubicin for superficial bladder cancer. Cochrane Database Syst Rev. 2010, Issue 1. Art. No.:CD008181. https://doi.org/10.1002/14651858.CD008181. ID - ref14 ER - TY - JOUR PY - 2002 DA - 2002// TI - Guidelines on bladder cancer JO - Eur Urol VL - 41 UR - https://doi.org/10.1016/S0302-2838(01)00026-4 DO - 10.1016/S0302-2838(01)00026-4 ID - ref15 ER - TY - JOUR AU - Dong, X. AU - Song, L. AU - Zhang, F. PY - 2017 DA - 2017// TI - Curative effect analysis of different chemotherapeutics at intravesical instillation in the prevention of tumor recurrence after TUR-Bt JO - Zhejiang J Traumat Surg VL - 22 ID - Dong2017 ER - TY - JOUR AU - Lin, T. AU - Sun, L. PY - 2016 DA - 2016// TI - Comparison of the efficacy of different chemotherapy drugs in the prevention of postoperative recurrence in superficial bladder cancer by intravesical instillation JO - China Foreign Med Treat VL - 35 ID - Lin2016 ER - TY - JOUR AU - Sun, S. AU - Liu, R. AU - Zhao, H. PY - 2016 DA - 2016// TI - Comparison of intravesical perfusion of gemcitabine and mitomycin after non-muscle invasive bladder cancer JO - J Med Theory Pract VL - 29 ID - Sun2016 ER - TY - JOUR AU - Xiaohong, Z. AU - Tan, J. AU - Wei, Y. PY - 2015 DA - 2015// TI - Clinical effect of antineoplastic drug perfusion in preventing postoperative recurrence of superficial bladder cancer JO - J Chin Physician VL - 17 ID - Xiaohong2015 ER - TY - JOUR AU - Addeo, R. AU - Caraglia, M. AU - Bellini, S. PY - 2010 DA - 2010// TI - Randomized phase III trial on gemcitabine versus Mitomycin in recurrent superficial bladder Cancer: evaluation of efficacy and tolerance JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2008.20.8199 DO - 10.1200/JCO.2008.20.8199 ID - Addeo2010 ER - TY - JOUR AU - Lau, J. AU - Ioannidis, J. P. AU - Schmid, C. H. PY - 1998 DA - 1998// TI - Summing up evidence: oneanswer is not always enough JO - Lancet. VL - 351 UR - https://doi.org/10.1016/S0140-6736(97)08468-7 DO - 10.1016/S0140-6736(97)08468-7 ID - Lau1998 ER - TY - BOOK AU - Shariat, S. F. AU - Chade, D. C. AU - Karakiewicz, P. I. AU - Scherr, D. S. AU - Dalbagni, G. PY - 2010 DA - 2010// TI - Update on intravesical agents for non-muscle-invasive bladder cancer. Immunotherapy ID - Shariat2010 ER - TY - JOUR AU - Shelley, M. D. AU - Jones, G. AU - Cleves, A. PY - 2012 DA - 2012// TI - Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review JO - BJU Int VL - 109 UR - https://doi.org/10.1111/j.1464-410X.2011.10880.x DO - 10.1111/j.1464-410X.2011.10880.x ID - Shelley2012 ER - TY - STD TI - Peyton CC, Chipollini J, Azizi M, et al. Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what. World J Urol. 2018. https://doi.org/10.1007/s00345-018-2591-1. ID - ref24 ER - TY - JOUR AU - Stein, J. P. AU - Lieskovsky, G. AU - Cole, R. PY - 2001 DA - 2001// TI - Radical cystectomy in the treatment of invasive bladder cancer: long term results in 1054 patients JO - J Clin Oncol VL - 19 UR - https://doi.org/10.1200/JCO.2001.19.3.666 DO - 10.1200/JCO.2001.19.3.666 ID - Stein2001 ER - TY - JOUR AU - Schlack, K. AU - Boegemann, M. AU - Steinestel, J. AU - Schrader, A. J. AU - Krabbe, L. M. PY - 2016 DA - 2016// TI - The safety and efficacy of gemcitabine for the treatment of bladder cancer JO - Expert Rev Anticancer Ther VL - 16 UR - https://doi.org/10.1586/14737140.2016.1143777 DO - 10.1586/14737140.2016.1143777 ID - Schlack2016 ER - TY - JOUR AU - Messing, E. M. AU - Tangen, C. M. AU - Lerner, S. P. PY - 2018 DA - 2018// TI - Effect of Intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder Cancer on tumor recurrence: SWOG S0337 randomized clinical trial JO - JAMA. VL - 319 UR - https://doi.org/10.1001/jama.2018.4657 DO - 10.1001/jama.2018.4657 ID - Messing2018 ER - TY - JOUR AU - Dalbagni, G. AU - Russo, P. AU - Bochner, B. PY - 2006 DA - 2006// TI - Phase II trial of intravesical gemcitabine in bacille Calmette Guerin-refractory transitional cell carcinoma of the bladder JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2005.05.2720 DO - 10.1200/JCO.2005.05.2720 ID - Dalbagni2006 ER - TY - JOUR AU - Bartoletti, R. AU - Cai, T. AU - Gacci, M. PY - 2005 DA - 2005// TI - Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study JO - Urology. VL - 66 UR - https://doi.org/10.1016/j.urology.2005.04.062 DO - 10.1016/j.urology.2005.04.062 ID - Bartoletti2005 ER - TY - JOUR AU - Bolenz, C. AU - Cao, Y. AU - Arancibia, M. F. PY - 2006 DA - 2006// TI - Intravesical mitomycin C for superficial transitional cell carcinoma JO - Expert Anticancer Ther VL - 6 UR - https://doi.org/10.1586/14737140.6.8.1273 DO - 10.1586/14737140.6.8.1273 ID - Bolenz2006 ER - TY - JOUR AU - Jones, G. AU - Cleves, A. AU - Wilt, T. J. AU - Mason, M. AU - Kynaston, H. G. AU - Shelley, M. PY - 2012 DA - 2012// TI - Intravesical gemcitabine for non-muscle invasive bladder cancer JO - Cochrane Database Syst Rev VL - 1 ID - Jones2012 ER - TY - STD TI - Centers for Medicare & Medicaid Services. 2020 ASP Drug Pricing Files. https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2020-asp-drug-pricing-files. Accessed 5 Jan 2020. UR - https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2020-asp-drug-pricing-files ID - ref32 ER -